Application of infrared matrix-assisted laser desorption electrospray ionization mass spectrometry for morphine imaging in brain tissue-Reference-Cited by-同舟云学术

Application of infrared matrix-assisted laser desorption electrospray ionization mass spectrometry for morphine imaging in brain tissue

Published:2023-07-25 Issue:23 Volume:415 Page:5809-5817
ISSN:1618-2642
Container-title:Analytical and Bioanalytical Chemistry
language:en
Short-container-title:Anal Bioanal Chem

Author:

Desyaterik Yury^ORCID,Mwangi Joseph N.,McRae MaryPeace,Jones Austin M.,Kashuba Angela D. M.^ORCID,Rosen Elias P.^ORCID

Abstract

AbstractHere, we present a method developed for the analysis of spatial distributions of morphine in mouse brain tissue using infrared matrix-assisted laser desorption electrospray ionization (IR-MALDESI) coupled to a Q Exactive Plus mass spectrometer. The method is also capable of evaluating spatial distributions of the antiretroviral drug abacavir. To maximize sensitivity to morphine, we analyze various Orbitrap mass spectrometry acquisition modes utilizing signal abundance and frequency of detection as evaluation criteria. We demonstrate detection of morphine in mouse brain and establish that the selected ion monitoring mode provides 2.5 times higher sensitivity than the full-scan mode. We find that distributions of morphine and abacavir are highly correlated with the Pearson correlation coefficient R = 0.87. Calibration showed that instrument response is linear up to 40 pg/mm2 (3.8 μg/g of tissue). Graphical abstract

Funder

National Institute on Drug Abuse

National Institute of Allergy and Infectious Diseases

The University of North Carolina at Chapel Hill Center for AIDS Research

Publisher

Springer Science and Business Media LLC

Subject

Biochemistry,Analytical Chemistry

Link

https://link.springer.com/content/pdf/10.1007/s00216-023-04861-x.pdf

Reference34 articles.

1. Valcour V, Chalermchai T, Sailasuta N, Marovich M, Lerdlum S, Suttichom D, Suwanwela NC, Jagodzinski L, Michael N, Spudich S, van Griensven F, de Souza M, Kim J, Ananworanich J, on behalf of the RV254/SEARCH 010 Study Group. Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis. 2012;206:275–82. https://doi.org/10.1093/infdis/jis326.

2. Cochrane CR, Angelovich TA, Byrnes SJ, Waring E, Guanizo AC, Trollope GS, Zhou J, Vue J, Senior L, Wanicek E, Eddine JJ, Gartner MJ, Jenkins TA, Gorry PR, Brew BJ, Lewin SR, Estes JD, Roche M, Churchill MJ. Intact HIV proviruses persist in the brain despite viral suppression with ART. Ann Neurol. 2022;92:532–44. https://doi.org/10.1002/ana.26456.

3. Tozzi V, Balestra P, Bellagamba R, Corpolongo A, Salvatori MF, Visco-Comandini U, Vlassi C, Giulianelli M, Galgani S, Antinori A, Narciso P. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. JAIDS J Acquir Immune Defic Syndr. 2007;45:174. https://doi.org/10.1097/QAI.0b013e318042e1ee.

4. Eggers C, Arendt G, Hahn K, Husstedt IW, Maschke M, Neuen-jacob E, Obermann M, Rosenkranz T, Schielke E, Straube E. HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment. J Neurol. 2017;264:1715–27. https://doi.org/10.1007/s00415-017-8503-2.

5. Fitting S, McRae M, Hauser KF. Opioid and neuroHIV comorbidity – current and future perspectives. J Neuroimmune Pharmacol. 2020;15:584–627. https://doi.org/10.1007/s11481-020-09941-8.